Clinical Trials Browser

Lymphoma × belinostat × Clear all

Liver Diseases, Lymphoma, Neoplasms

NCT02875002 2017-12-22

Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas

Phase 1 Withdrawn

Lymphoid

Lymphoma, Recurrence, Lymphoma, T-Cell

NCT02701673 2016-05-04

Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma

Phase 1/2 Withdrawn

Lymphoid

Lymphoma

NCT00413075 2015-07-08

Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

Phase 1 Completed

121 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther solid neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Fibrosarcoma, Head and Neck Neoplasms, Hemangiosarcoma, Hodgkin Disease, Kidney Neoplasms, Leiomyosarcoma, Liposarcoma, Lung Neoplasms, Lymphoma, Mesothelioma, Otorhinolaryngologic Neoplasms, Ovarian Neoplasms, Parathyroid Neoplasms, Prostatic Neoplasms, Sarcoma, Osteosarcoma, Thyroid Neoplasms, Colorectal Neoplasms, Lymphoma, B-Cell, Lymphoma, T-Cell, Adenosarcoma, Mixed Tumor, Mesodermal, Mesothelioma, Cystic, Carcinoma, Small Cell

Clinical Trials

Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction

Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas

Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma

Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma